Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Patrick G. Enright sold 352 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $133.19, for a total value of $46,882.88. Following the completion of the transaction, the director now directly owns 1,365 shares of the company’s stock, valued at approximately $181,804.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded up $0.85 on Thursday, reaching $138.04. The company’s stock had a trading volume of 294,400 shares, compared to its average volume of 512,903. The stock has a market cap of $8,224.61, a P/E ratio of 17.21, a P/E/G ratio of 0.81 and a beta of 1.00. Jazz Pharmaceuticals PLC has a one year low of $99.28 and a one year high of $163.75. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.94.

COPYRIGHT VIOLATION WARNING: “Patrick G. Enright Sells 352 Shares of Jazz Pharmaceuticals PLC (JAZZ) Stock” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/11/23/patrick-g-enright-sells-352-shares-of-jazz-pharmaceuticals-plc-jazz-stock.html.

JAZZ has been the subject of a number of research reports. Zacks Investment Research raised Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $174.00 price target for the company in a research note on Tuesday, August 8th. Deutsche Bank AG set a $175.00 price target on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Wednesday, August 9th. Royal Bank Of Canada reissued a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 9th. Janney Montgomery Scott reissued a “buy” rating and set a $192.00 price target (up from $180.00) on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 9th. Finally, J P Morgan Chase & Co reissued a “buy” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Monday, September 18th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have assigned a buy rating to the company’s stock. Jazz Pharmaceuticals PLC presently has an average rating of “Buy” and an average target price of $180.13.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JAZZ. Alliancebernstein L.P. increased its holdings in Jazz Pharmaceuticals PLC by 19.4% during the 1st quarter. Alliancebernstein L.P. now owns 4,211 shares of the specialty pharmaceutical company’s stock worth $611,000 after purchasing an additional 684 shares during the period. Dimensional Fund Advisors LP increased its holdings in Jazz Pharmaceuticals PLC by 4.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 154,195 shares of the specialty pharmaceutical company’s stock worth $22,378,000 after purchasing an additional 6,684 shares during the period. Mn Services Vermogensbeheer B.V. increased its holdings in Jazz Pharmaceuticals PLC by 507.6% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 9,727 shares of the specialty pharmaceutical company’s stock worth $1,513,000 after purchasing an additional 8,126 shares during the period. US Bancorp DE increased its holdings in Jazz Pharmaceuticals PLC by 94.4% during the 2nd quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after purchasing an additional 368 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in Jazz Pharmaceuticals PLC by 9.8% during the 2nd quarter. Russell Investments Group Ltd. now owns 16,576 shares of the specialty pharmaceutical company’s stock valued at $2,578,000 after acquiring an additional 1,483 shares in the last quarter. Institutional investors own 90.52% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.